

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KUANGCHI SCIENCE LIMITED

光啟科學有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 439)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

Reference is made to the annual report (the “**2019 Annual Report**”) of KuangChi Science Limited (the “**Company**”) for the year ended 31 December 2019. Capitalised terms used herein shall have the same meanings as those defined in the 2019 Annual Report unless the context requires otherwise.

In addition to the information disclosed in the 2019 Annual Report, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company would like to provide to the shareholders of the Company and the potential investors with the following supplementary information in the section headed “Management Discussion and Analysis” in the 2019 Annual Report:

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS OR DISPOSALS

KC Subscription in Kuang-Chi Technologies Co., Ltd. (“KCT”)

KCT, a PRC company listed on the Shenzhen Stock Exchange (stock code: 002625), is principally engaged in developing innovative advanced technology and its core business is in metamaterial intelligent structure and equipment research, as well as the manufacture of seat function components for automobiles.

As at 31 December 2019, the carrying amount of KCT is HK\$731,390,000 (2018: HK\$806,282,000), which represented 39.70% (2018: 37.52%) of the total assets of the Group.

Save as disclosed in this announcement, the remaining contents of the 2019 Annual Report remain unchanged.

By Order of the Board
KuangChi Science Limited
Dr. Liu Ruopeng
Chairman and Executive Director

Hong Kong, 29 July 2020

As at the date of this announcement, the board of directors comprises four executive directors, namely Dr. Liu Ruopeng, Dr. Luan Lin, Dr. Zhang Yangyang and Dr. Ji Chunlin; one non-executive director namely Mr. Li Chiu Ho; and three independent non-executive directors, namely Dr. Wong Kai Kit, Mr. Choi Wing Koon and Dr. Deng Ke.